Modulation of renal oxygenation and perfusion in rat kidney monitored by quantitative diffusion and blood oxygen level dependent magnetic resonance imaging on a clinical 1.5T platform

BMC Nephrol. 2016 Oct 3;17(1):142. doi: 10.1186/s12882-016-0356-x.

Abstract

Background: To investigate the combined use of intravoxel incoherent motion (IVIM) diffusion-weighted (DW) and blood oxygen level dependent (BOLD) magnetic resonance imaging (MRI) to assess rat renal function using a 1.5T clinical platform.

Methods: Multiple b-value DW and BOLD MR images were acquired from adult rats using a parallel clinical coil arrangement, enabling quantitation of the apparent diffusion coefficient (ADC), IVIM-derived diffusion coefficient (D), pseudodiffusion coefficient (D*) and perfusion fraction (f), and the transverse relaxation time T2*, for whole kidney, renal cortex, and medulla. Following the acquisition of two baseline datasets to assess measurement repeatability, images were acquired following i.v. administration of hydralazine, furosemide, or angiotensin II for up to 40 min.

Results: Excellent repeatability (CoV <10 %) was observed for ADC, D, f and T2* measured over the whole kidney. Hydralazine induced a marked and significant (p < 0.05) reduction in whole kidney ADC, D, and T2*, and a significant (p < 0.05) increase in D* and f. Furosemide significantly (p < 0.05) increased whole kidney ADC, D, and T2*. A more variable response to angiotensin II was determined, with a significant (p < 0.05) increase in medulla D* and significant (p < 0.05) reduction in whole kidney T2* established.

Conclusions: Multiparametric MRI, incorporating quantitation of IVIM DWI and BOLD biomarkers and performed on a clinical platform, can be used to monitor the acute effects of vascular and tubular modulating drugs on rat kidney function in vivo. Clinical adoption of such functional imaging biomarkers can potentially inform on treatment effects in patients with renal dysfunction.

Keywords: Angiotensin; BOLD; Diffusion; Furosemide; Hydralazine; Imaging; Renal.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / pharmacology
  • Animals
  • Antihypertensive Agents / pharmacology
  • Diffusion / drug effects*
  • Diffusion Magnetic Resonance Imaging / methods
  • Diuretics / pharmacology
  • Female
  • Furosemide / pharmacology
  • Hydralazine / pharmacology
  • Kidney / diagnostic imaging*
  • Kidney / metabolism*
  • Kidney / physiology
  • Magnetic Resonance Imaging / methods*
  • Oxygen / blood
  • Oxygen / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Reproducibility of Results
  • Vasoconstrictor Agents / pharmacology

Substances

  • Antihypertensive Agents
  • Diuretics
  • Vasoconstrictor Agents
  • Angiotensin II
  • Hydralazine
  • Furosemide
  • Oxygen